T1	Participants 763 828	36 patients in the control group, 14 with positive urine cytology
T2	Participants 881 915	22 patients with negative cytology
T3	Participants 1138 1198	72 patients in the Pirarubicin Monotherapy Study Group trial
T4	Participants 1232 1304	Among the 31 patients, 17 patients who received pirarubicin instillation
T5	Participants 1346 1388	14 patients who received control treatment
